Protactinium is a real chemical element but not a commercial commodity. The authoritative IUPAC review notes that primordial Pa has long since disappeared from Earth and that the only terrestrial source is ongoing radioactive decay of heavier elements, principally in uranium ores, where Pa-231 and Pa-234 occur in equilibrium proportions. In practice that means protactinium exists as a trace radiochemical separation problem, not as a mined or refined supply chain [iupac_pa_review_2000; iupac_iptei_pa].

Modern work is research-driven and isotope-specific. ORNL's 2024 Analytical Chemistry paper describes separating Pa-230 from proton-irradiated Th-232 targets as part of a medical-isotope workflow for harvesting ingrown U-230. That is the relevant commercial reality for 2025: protactinium appears in specialist nuclear laboratories as an intermediate or research radionuclide, with no published reserves, no quoted market price, and no country-level mine or refining statistics [ornl_pa230_sep_2024].